BIO International Convention is back in Boston, June 4-7, to celebrate history-making innovation. Sidam will participate at this event where the global biotech and pharma community is going to gather, with more than 150 education sessions and a network of 16,000+ attendees from 74 countries. Please come to meet us at Booth #743, Italy Pavilion.
The company has won the 'Imprese X Innovazione - Andrea Pininfarina Award’, assigned by Confindustria for having successfully invested in research and innovation.
This is the first innovation award in Europe to have adopted the parameters of the European Foundation for Quality Management (EFQM) and participates, for the Industry and Services category, to the Prize of Prizes, an award set up by the President of the Council of Ministers on a mandate by the President of the Italian Republic.
Sidam confirms its support for the important event of Mirandola, confirming the commitment it has always shown towards the territory and the social.
The Memory Festival winds through the squares, streets, arcades, gardens and palaces of the city offering appointments with numerous Italian protagonists of culture, thought and entertainment, ranging between disciplines and different themes, always in mutual dialogue around the memory.
Particularly noteworthy is the appointment on Saturday 9 June at 11:00 with Massimo Dominici and Ilaria Vesentini on "The biomedical district: the memory of the future"
We acquired a 75% stake in BTC Medical Europe, leader company in the postoperative blood recovery and oncology sectors and based in Valeggio sul Mincio (VR) and in Nonantola (MO).
The goal is to establish an entirely Italian biomedical centre and to enhance our portfolio of products and markets.
Another important milestone reached by Sidam: Mirandola's production site obtained from FDA (Food and Drug Administration) the Registration Number, which qualifies the company as a production workshop authorized to produce for the United States of America. This certification ensures, also for the North American market, the safety and efficacy of biomedical devices produced by the company, already recognized by the various awarding bodies responsible for Europe, South America and Asia. This recognition will allow Sidam to significantly expand its international business opportunities in the biomedical sector.